Migraine affects an estimated 39 million Americans, and roughly one in four households in the United States has someone living with attacks. For decades, the cannabis-and-migraine conversation has been carried by patient stories and observational data. That changed in early 2026 when the first randomized, double-blind, placebo-controlled crossover trial of vaporized cannabis for acute migraine was published in the peer-reviewed journal Headache.[1]
The headline finding: vaporized flower containing 6% THC plus 11% CBD outperformed placebo on the trial's primary measures of pain relief. The full picture is more nuanced, and it matters for anyone in New York who has been wondering whether cannabis has a real place in a migraine plan. Here is what the new research suggests, where it stops short, and how to think about strain and terpene selection if you and your clinician decide to explore the option.
The 2026 UC San Diego Trial
Researchers at the UC San Diego Center for Pain Medicine, led by headache neurologist Dr. Nathaniel Schuster, enrolled 92 adults with episodic migraine. Participants treated up to four acute attacks at home within four hours of onset, rotating through four randomized treatments: 6% THC flower, 11% CBD flower, a 6% THC / 11% CBD combination, and placebo flower. In total, 247 migraine attacks were treated, making this the largest controlled trial of inhaled cannabis for migraine to date.[1]
At the two-hour primary endpoint, the THC plus CBD combination delivered pain relief to 67.2% of participants compared with 46.6% on placebo. Complete pain freedom reached 34.5% with the combination versus 15.5% with placebo, and freedom from the most bothersome symptom (typically nausea, light sensitivity, or sound sensitivity) reached 60.3% versus 34.5%.[1] Benefits were sustained at 24 and 48 hours for several measures.
Two other findings deserve attention. THC alone produced more side effects, including dizziness and feeling intoxicated, than the THC plus CBD combination, supporting the idea that CBD may temper some of THC's less desirable acute effects. And CBD alone did not separate from placebo on the primary pain freedom measure, suggesting that THC is likely doing meaningful work in the combination.[2]
A Long-Term Look from the UK Registry
A separate 2026 observational analysis followed 203 adults in the UK Medical Cannabis Registry who had been prescribed cannabis-based medicines for migraine after failing conventional treatments. At two years, 54% of patients met a clinically meaningful improvement threshold on the Headache Impact Test, and 67% reported improvements in overall quality of life.[3]
Registry data cannot prove that cannabis caused the improvements, which is why the authors are careful to call for additional randomized trials. Still, the long-term tolerability and the consistency of patient-reported benefit add useful context to the controlled trial results.
What Patient Surveys Say About Strains and Terpenes
Patient survey research, including a New York cohort of 316 chronic migraine patients, suggests that people who report headache relief from cannabis tend to gravitate toward strains rich in two specific terpenes: beta-caryophyllene and beta-myrcene.[4] Surveys are observational, so the findings should be read as patterns rather than proof, but they line up with what is known about these terpenes biologically.
Beta-caryophyllene is the warm, peppery terpene that also interacts directly with the body's CB2 cannabinoid receptors, which are involved in inflammation and stress response. Beta-myrcene, with its earthy, slightly fruity aroma, is the most common terpene in cannabis and is most often associated with relaxing, body-heavy effects.[5] For a deeper read on how terpenes shape your experience, see our guide to the entourage effect.
If you want to experiment, here are three Greenline strains that fit the profile patient surveys describe most often:
What the Research Does Not Say
It is worth being clear about the limits. The 2026 trial measured a single dosing protocol (one standardized inhalation regimen of vaporized flower) in adults with episodic migraine, not chronic daily headache, cluster headache, or pediatric migraine. Researchers did not compare vaporized cannabis directly against triptans or CGRP inhibitors, so the new data does not tell us how cannabis ranks against first-line abortive medications.[1]
Side effects matter too. Even in the better-tolerated THC plus CBD arm, participants reported short-term dizziness, dry mouth, and feeling intoxicated more often than on placebo. Cannabis can also interact with other medications, and frequent use carries its own risk profile that is separate from acute use during an attack.
A Practical Framework for New Yorkers
Adult-use cannabis is legal for New Yorkers 21 and older, and a growing list of licensed dispensaries across the state stock vaporizable flower as well as concentrates and edibles. The new evidence does not replace working with a clinician, especially if you have frequent migraines or are already on medication. It does, however, give you a clearer starting point for an informed conversation, and a few practical principles for choosing product.
Favor balanced THC and CBD products. The trial's most consistent benefits showed up with the combination, not THC alone.
Choose a fast-onset format. Vaporized flower was studied because it acts within minutes, which matters during an active attack. Edibles, with their 30 to 90 minute onset, are usually a poor fit for acute use.
Read the terpene panel, not just the THC percentage. Patient data points toward beta-caryophyllene and beta-myrcene profiles. Greenline's strains feature detailed terpene reporting on every package.
Start low. A small dose and a quiet environment is the right way to learn how a specific strain affects you, especially if you have not used cannabis frequently.
The Bottom Line
For years, the cannabis-and-migraine question lived in the gap between strong patient enthusiasm and weak controlled evidence. The 2026 UC San Diego trial begins to close that gap. It suggests that vaporized THC plus CBD may help acute migraine in a way placebo does not, while pointing out that more research is needed to map dose, format, and population. Combined with long-term registry data and patient survey findings on terpene preferences, it gives consumers and clinicians a more honest, less hype-driven starting point.
Our flower is crafted with full terpene reporting and consistent quality, so you can build a plan that matches the research rather than guessing. Browse our full strain menu or find a licensed dispensary near you to get started.
Frequently Asked Questions
Does cannabis help with migraines according to the latest research?
Early evidence suggests it may. A 2026 randomized, double-blind, placebo-controlled crossover trial published in the journal Headache found that vaporized 6% THC combined with 11% CBD was superior to placebo for pain relief, pain freedom, and freedom from the most bothersome migraine symptom at the two-hour mark. Researchers note that more studies are needed and that cannabis is not a substitute for a treatment plan from a qualified clinician.
What did the 2026 UC San Diego cannabis migraine study find?
The UC San Diego team led by Dr. Nathaniel Schuster enrolled 92 adults with migraine and randomized 247 attacks across four treatments: THC only, CBD only, a THC and CBD combination, and placebo. Two hours after treatment, pain relief reached 67.2% with the THC plus CBD combination versus 46.6% with placebo. Benefits were sustained at 24 and 48 hours for the combination arm. THC alone produced more side effects than the combination, while CBD alone did not separate from placebo on the primary endpoint.
Which terpenes do migraine patients tend to prefer?
Patient survey research suggests that strains rich in beta-caryophyllene and beta-myrcene are commonly reported as helpful by people using cannabis for headache and migraine symptoms. These are early, observational findings rather than definitive clinical evidence, so individual responses can vary widely.
Is vaporized cannabis better than other forms for migraine?
The 2026 randomized trial specifically studied vaporized flower because it allows for rapid onset, which matters for acute migraine attacks. Researchers have not yet directly compared vaporization to edibles, tinctures, or other formats for migraine in head-to-head trials, so it is premature to call any single format the best option.
What does cannabis for migraine mean for New York consumers?
Adult-use cannabis is legal for New Yorkers 21 and older, and licensed dispensaries throughout the state stock vaporizable flower as well as concentrates and edibles. The new research does not change medical advice, but it does add to the case for working with a knowledgeable budtender to find balanced THC and CBD products, paying attention to terpene profiles, and starting with a low dose.
References
- Schuster NM, Wallace MS, Marcotte TD, et al. Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70025
- NeurologyLive. Final analyses highlight efficacy of THC-CBD combination therapy for acute migraine. 2025. neurologylive.com
- Marijuana Herald. Study: Cannabis-based treatments linked to long-term improvements in migraine symptoms and quality of life. 2026. themarijuanaherald.com
- Baron EP, Lucas P, Eades J, Hogue O. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. The Journal of Headache and Pain. 2018;19:37. doi:10.1186/s10194-018-0862-2
- LaVigne JE, Hecksel R, Keresztes A, et al. Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity. Scientific Reports. 2021;11:8232. doi:10.1038/s41598-021-87740-8
Find your match.
Explore Greenline Strains